Table 3. Univariate and multivariate analysis in patients that received cytotoxic chemotherapy using Cox proportional hazards model.
| N=55 | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| Factor | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Gender (Male / Female) | 0.9 (0.51–1.63) | 0.73 | |||
| Age yr (≥ 65 / < 65) | 0.82 (0.47–1.46) | 0.51 | |||
| Smoking (Smoker / Never Smoker) | 1.2 (0.67–2.21) | 0.55 | |||
| ECOG-PS (PS ≥ 2 / PS 0–1) | 4.12 (0.94–12.84) | *0.06 | > | 1.45 (0.32–4.85) | 0.59 |
| Stage (IV / recurrence / III) | 0.6 (0.28–1.59) | 0.28 | |||
| Histology (Non-ad / Ad) | 1.48 (0.8–2.64) | 0.21 | |||
| EGFR-status (Negative or Sq / mutant) | 2.3 (1.09–5.66) | *0.03 | > | 5.96 (2.29–17.85) | *< 0.01 |
| Monotherapy (Monotherapy / Platinum Doublet) | 2.06 (1.09–3.78) | *0.03 | |||
| Second-line (2nd-line / 1st-line) | 2.01 (1.12–3.63) | *0.02 | > | 2.11 (1.14–3.94) | *0.02 |
| sHGF at pre-treatment (Positive / Negative) | 1.25 (0.68–2.26) | 0.45 | |||
| sHGF at response-evaluation (Positive / Negative) | 2.1 (1.18–3.73) | *0.01 | > | 4.24 (2–9.25) | *< 0.01 |
HR: hazard ratio; ECOG: Eastern Cooperative Oncology Group; PS: performance status; Ad: adenocarcinoma; EGFR: epidermal growth factor receptor; Sq: squamous cell carcinoma.